home / stock / celuw / celuw news

CELUW News and Press, Celularity Inc. Warrant

Stock Information
Company Name: Celularity Inc. Warrant
Stock Symbol: CELUW
Market: NASDAQ
Website: celularity.com
Menu
CELUW CELUW Quote CELUW Short CELUW News CELUW Articles CELUW Message Board
Get CELUW Alerts

News, Short Squeeze, Breakout and More Instantly...
CELUW - Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are pote...
CELUW - Celularity secures strategic license deal worth up to $35M for biomaterials portfolio

2026-03-10 08:45:12 ET More on Celularity Seeking Alpha’s Quant Rating on Celularity Financial information for Celularity Read the full article on Seeking Alpha For further details see: Celularity secures strategic license deal worth up to $35M for...

CELUW - Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Transaction expected to generate up to $35 million in upfront and milestone payments Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunity Organizational realignment reduces operating expenses and sharpens focus on longevity therapeuti...

CELUW - Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unu...
CELUW - Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Cent...

CELUW - Celularity Announces Closing of Financing Transactions

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Phi...

CELUW - Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance. FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celular...
CELUW - Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a n...

CELUW - Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease Celularity PDA-002 achieved durable wound healing with just two intramuscular doses As a qualified stem cell therapy under Florida statute (§ 458.3245), effective J...

CELUW - Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan. Company also announces notification by Nasdaq dated September 2, 2025, that it now...
Next 10